Research

We strive to develop new chemical tools to advance biomedical applications and disease treatment (Chem4Biomed), with a heavy focus on immunotherapies and regenerative medicine, through seamless collaboration with biomedical engineers, clinicians, and companies.

Figure 1. Chem4Biomed in the Xia lab.

Our research has gone through various phases over the past years. For example, project cluster 1 evolved from site-selective protein reactions to antibody modifications and then to immunotherapies. The trajectory is summarized below.

Figure 2. From site-selective protein reaction to antibody conjugates and immunotherapies.

Project cluster 2 also evolved a long way, stimulated by various inspirations, from multienzyme assembly to liquid-liquid phase separation. The following figure shows the evolution route.

Figure 3. From multienzyme complexes to liquid-liquid phase separation.